Methylation markers identify high risk patients in IGHV mutated chronic lymphocytic leukemia

 Abstract

Chronic lymphocytic leukemia (CLL) exhibits a very variable clinical course. Altered DNA methylation of genes has shown promise as a source of novel prognostic makers in a number of cancers. Here we have studied the potential utility of a panel of methylation markers (CD38, HOXA4 and BTG4) in 118 CLL patients. Each of the three loci assessed exhibited frequent methylation, as determined by COBRA analysis, and individually correlated with either good (CD38, BTG4 methylation) or poor (HOXA4 methylation) prognosis. Using a combined approach to produce an overall methylation score, we found that methylation score was significantly associated with time to first treatment in CLL patients. Multivariate Cox regression analysis revealed that methylation score was the strongest predictor of time to first treatment, and was independent of IGHV gene mutational status and CD38 expression. This study provides proof of principle that a panel of methylation markers can be used for additional risk stratification of CLL patients.

Full Text Options
Article
Metrics
 Share
 Full Text
 Info
Pages
300 - 306
doi
10.4161/epi.6.3.14038
Type
Brief Report
 Metrics
 Cite This Article
 Permissions
 Permissions
 Reprints
Methylation markers identify high risk patients in IGHV mutated chronic lymphocytic leukemia